10/02/2016

Bangladesh Annual Pharma Market 2015-2016

Bangladesh pharmaceutical industry is mainly dominated by domestic manufacturers. Before 1982 there were about 10 multinational companies availing about 80% of the domestic market. The situation is reverse now. Of the total pharmaceutical market of Bangladesh, the local companies are enjoying a market share reaching around 80%, while the multinational companies are having a market share of around 20%. According to IMS Health, annual pharmaceutical sales in the local market may reach BDT 160 billion within 2018. The top pharmaceutical manufacturers in Bangladesh are- Square, Incepta, Beximco, Opsonin, Eskayef, Renata, Aristopharma, ACI, ACME,  Healthcare, Drug International Ltd. etc.

According to IMS report the annual growth of Bangladesh pharma market is -

[2009] 16.83%
[2010] 23.8%
[2011] 23.6%
[2012] 13.5%
[2013] 8.12%
[2014] 9.97%
[2015] 13.85%
[2016, 3rd Quarter] 38.31%

The year 2015 was more important for the pharmaceutical market in Bangladesh as it again uphold various developing trends. Significantly, the overall declining growth rate of the last three to four years is strongly reversed in 2015-2016. The top 10 pharmaceutical companies growth rate sharply increased in 2015-2016 compared to previous years.

According to IMS report (2015-16), the top 5 pharmaceutical companies in Bangladesh are-

  1. Square Pharmaceuticals Ltd.
  2. Incepta Pharmaceuticals Ltd.
  3. Beximco Pharmaceuticals Ltd.
  4. Renata Limited.
  5. Opsonin Pharma Ltd.

This year (2016) many of them start to export high quality product in high rated pharma market including USA, UK, and Australia. In this connection, several pharma manufacturers have already made huge investments in their new state of art manufacturing facilities. A number of companies have already obtained or in the process of obtaining UKMHRA, EU, TGA, and GCC certifications. They are also looking for high rated pharma markets to export their products in upcoming year 2017.

Though overall long-run prospects for the generics industries become more updated, but in value terms the global product pipeline appears rich, most of the high-value additions are in the biotechnology field and notoriously expensive to develop. Therefore, for the foreseeable future they have lack of opportunities for any blockbuster generic.


Related Posts

No comments:

Post a Comment

Popular Articles